Canada markets close in 4 hours 34 minutes

Xeno Transplants Corporation (XENO)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.00000.0000 (0.00%)
As of 12:52PM EST. Market open.

Xeno Transplants Corporation

143 Gardner Road
Brookline, MA 02445
United States

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Wayne SmithChief Financial Officer, Sec., Treasurer and Director20.96kN/A1957
Dr. Elliot Lebowitz Ph.D.Chief Exec. Officer, Pres and DirectorN/AN/A1942
Amounts are as of December 31, 2007 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Xeno Transplants Corporation operates as a bio-technology research and development company. The company, through a license agreement with Massachusetts General Hospital, intends to develop, manufacture, distribute, and use products and processes for public use with regard to xenotransplantation. The Xenotransplantation is intended to address the problems arising from the limited supply of available human cells, tissues, and organs for transplantation by developing technologies to permit the transplantation of cells, tissues, and organs from other species into humans, such as swine. Xeno Transplants Corporation was incorporated in 2004 and is based in Brookline, Massachusetts.

Corporate Governance

Xeno Transplants Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.